FiercePharma  Oct 1  Comment 
BioMarin Pharmaceutical bet more than half a billion dollars on the rare disease phenylketonuria Thursday. The U.S.-based biotech will pay its development partner Merck KGaA 340 million euros up front for worldwide rights to Kuvan (excluding...
Benzinga  Oct 1  Comment 
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that it has acquired all global rights to Kuvan® (sapropterin dihydrochloride) and pegvaliase from Merck Serono (Merck). Under the terms of the agreement, BioMarin will provide Merck...
Benzinga  Sep 30  Comment 
Shares of PHI Inc. (NASDAQ: PHIIK) were up almost 6 percent in Wednesday’s after-hours session, recuperating some of the ground lost (9.06 percent) during the day. PBF Energy Inc (NYSE: PBF) was up more than 8 percent after the company...
Market Intelligence Center  Sep 30  Comment 
BioMarin Pharmaceutical (BMRN) traded between $95.09 and $104.65 before closing at $96.82 Tuesday and presents some attractive trading opportunities today according to MarketIntelligenceCenter.com's patented algorithms. The computer program that...
Forbes  Sep 28  Comment 
In early trading on Monday, shares of Intel Corp (INTC) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.3%. Year to date, Intel Corp has lost about 19.6% of its value.
The Times of India  Sep 22  Comment 
The Californiabased BioMarin Pharmaceutical has entered into a settlement agreement with Dr Reddy's Laboratories to resolve patent litigation in the US regarding Kuvan, the former's 100mg oral tablets.
The Hindu Business Line  Sep 21  Comment 
As part of the pact, BioMarin will grant Dr Reddy’s a non-exclusive licence to market a generic version of Kuvan tablets in the due course.


BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.



BioMarin competes with companies like:


  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki